Tandem Diabetes Care (Nasdaq:TNDM) announced that it acquired infusion set developer Capillary Biomedical.
San Diego-based Tandem, a global insulin delivery and diabetes technology company, announced its intention to acquire Irvine, California-based Capillary last week. Financial terms for the deal were not disclosed.
“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” Tandem President and CEO John Sheridan said in a news release. “Through this acquisition, and through our efforts with existing infusion set partners, we look forward to developing new and innovative infusion set solutions that are designed to extend wear time and enhance user experience, while reducing occlusions, body burden and waste.”
Capillary Biomedical’s unique extended wear infusion set technology is currently in development and not commercially available. The company designed its SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability.
The SteadiSet infusion set, powered by the SteadiFlow technology platform, includes an integrated inserter designed for an easy, painless, hidden needle, one-handed insertion. The entire set includes materials to reduce preservative loss for improved insulin stability and reduced aggregate formation. Capillary Biomedical received FDA investigational device exemption for the platform in January of this year.
Meanwhile, Tandem develops the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.
Recent data presented by the company in April demonstrated that use of the t:slim X2 with Control-IQ technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management.
Further study results from the ongoing real-world Control-IQ observational (CLIO) study demonstrated immediate and sustained benefits in a diverse cohort of participants. All ethnic cohorts experienced psychosocial benefits, Tandem said, while all participants using the system also noted significantly improved quality of sleep.